Please use this identifier to cite or link to this item:
Title: Plasma Amyloid-β Biomarker Associated with Cognitive Decline in Preclinical Alzheimer's Disease.
Austin Authors: Lim, Yen Ying;Maruff, Paul;Kaneko, Naoki;Doecke, James;Fowler, Christopher;Villemagne, Victor L ;Kato, Takashi;Rowe, Christopher C ;Arahata, Yutaka;Iwamoto, Shinichi;Ito, Kengo;Tanaka, Koichi;Yanagisawa, Katsuhiko;Masters, Colin L ;Nakamura, Akinori
Affiliation: Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Aichi, Japan
The Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Clayton, VIC, Australia
Koichi Tanaka Mass Spectrometry Research Laboratory, Shimadzu Corporation, Kyoto, Japan
National Hospital for Geriatric Medicine, National Center for Geriatrics and Gerontology, Obu, Aichi, Japan
The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Aichi, Japan
Molecular Imaging and Therapy
Health and Biosecurity, CSIRO, Brisbane, Australia
Cogstate Ltd., Melbourne, VIC, Australia
Issue Date: 2020
Date: 2020-08-17
Publication information: Journal of Alzheimer's Disease : JAD 2020; 77(3): 1057-1065
Abstract: Using immunoprecipitation-mass spectrometry, we recently developed and validated a plasma composite biomarker for the assessment of amyloid-β (Aβ) levels. However, as yet, its relationship with clinical outcomes remains unclear. We aimed to examine the relationship between this plasma Aβ composite biomarker and cognitive function in cognitively normal older adults in two independent cohorts. Participants enrolled in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study and the National Centre for Geriatrics and Gerontology (NCGG) study had undergone Aβ neuroimaging using positron emission tomography (PET), cognitive assessments and provided blood samples. We derived a high-performance plasma Aβ composite biomarker by immunoprecipitation with mass-spectrometry. Both continuous and categorical measures of the plasma Aβ composite biomarker were significantly related to decline in episodic memory and executive function. The magnitude of effects of the plasma Aβ composite on episodic memory and executive function were comparable to that observed for the effects of PET Aβ levels on these same outcome measures. Several plasma Aβ biomarkers have been developed, but none have yet been applied to investigate their relationship with cognitive outcomes. Our results have important implications for the use of this biomarker in the detection of at-risk individuals.
DOI: 10.3233/JAD-200475
Journal: Journal of Alzheimer's Disease : JAD
PubMed URL: 32925048
Type: Journal Article
Subjects: Amyloid-β
plasma biomarker
preclinical Alzheimer’s disease
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Sep 29, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.